Table 1

Baseline characteristics and rates of follow-up of stage 1 serological suspects, by site

Adjumani, Uganda

Arua, Uganda

Moyo, Uganda

Yumbe, Uganda

Kiri, s. Sudan

Maridi, s. Sudan

Total




Number of patients

1140

2215

296

81

2201

730

6663




Baseline characteristics

Median age (IQR)

20 (12–32)

25 (14–35)

22 (12–36)

25 (13–40)

21 (13–32)

23 (15–35)

20 (12–33)

Number female (%)

595 (52.2)

1148 (51.8)

166 (56.1)

44 (54.3)

1231 (55.9)

386 (52.8)

3570 (53.6)

Number screened actively (%)

853 (74.8)

1362 (61.5)

239 (80.7)

14 (17.3)

926 (42.1)

165 (22.6)

3559 (53.4)

Number with zero WBC in CSF† (%)

607 (53.2)

1027 (46.4)

194 (65.5)

21 (25.9)

1052 (47.8)

9 (0.02)

2910 (43.7)




Follow-up rates

Not seen during follow-up (%)

660 (57.9)

410 (18.5)

249 (84.1)

47 (58.0)

1502 (68.2)

617 (84.5)

3485 (52.3)

Seen at least once (%)

480 (42.1)

1805 (81.5)

47 (15.9)

34 (42.0)

699 (31.8)

113 (15.5)

3178 (47.7)

Seen at 3 months (%)

250 (21.9)

1180 (53.3)

23 (7.8)

25 (30.9)

412 (18.7)

63 (8.6)

1953 (29.3)

Seen at 6 months (%)

112 (9.8)

570 (25.7)

15 (2.1)

11 (13.6)

135 (6.1)

15 (2.0)

850 (12.8)

Seen at 9 months (%)

61 (5.3)

299 (13.5)

2 (0.7)

4 (4.9)

53 (2.4)

11 (1.5)

430 (6.5)

Seen at 12 months (%)

63 (5.5)

366 (16.5)

6 (2.0)

6 (7.4)

60 (2.7)

9 (1.2)

510 (7.6)

Median person-days of observation†† (IQR)

169 (98–277)

177 (97–328)

110 (97–201)

151 (98–271)

128 (96–209)

117 (93–198)

158 (97–281)


IQR = inter-quartile range; WBC = white blood cells; CSF = cerebrospinal fluid

†Note that all patients had ≤5 WBC/μL, as per stage 1 suspect definition. Presence of low WBC densities is generally not considered evidence of CSF infection, and the threshold of 5 cells/μL is also used in neurology.

††Among patients seen at least once.

Checchi et al. BMC Infectious Diseases 2008 8:16   doi:10.1186/1471-2334-8-16

Open Data